Literature DB >> 29428312

Reproductive and metabolic determinants of granulosa cell dysfunction in normal-weight women with polycystic ovary syndrome.

Annie A Guedikian1, Alexandria Y Lee1, Tristan R Grogan2, David H Abbott3, Karla Largaespada1, Gregorio D Chazenbalk1, Daniel A Dumesic4.   

Abstract

OBJECTIVE: To determine the degree to which E2 hyperresponsiveness to FSH and antimüllerian hormone (AMH) overproduction in normal-weight women with polycystic ovary syndrome (PCOS) correlate with increased antral follicle number (AFN), hyperandrogenism, and/or metabolic dysfunction.
DESIGN: Prospective cohort study.
SETTING: Academic medical center. PATIENT(S): Seven normal-weight women with PCOS (1990 National Institutes of Health criteria) ages 20-34 years and 13 age- and body mass index- (BMI-; 18.5-25 kg/m2) matched normoandrogenic ovulatory women were studied. INTERVENTION(S): All women underwent basal serum hormone and metabolic measurements, FSH stimulation testing with transvaginal ovarian sonography, frequently sampled IV glucose tolerance testing, and whole-body dual-energy x-ray absorptiometry. MAIN OUTCOME MEASURE(S): Serum hormone/metabolite levels, 24-hour serum E2 response to 150 IU recombinant human (rh) FSH infusion, AFN, insulin sensitivity, and body mass measurements. RESULT(S): Serum E2 responsiveness to rhFSH and AMH levels were greater in women with PCOS than in BMI- and age-matched control women, as were serum androgen levels, AFN, and abdominal fat mass. In all women combined, serum E2 responsiveness to rhFSH was associated with AFN. Serum AMH levels, however, positively correlated with AFN but remained positively correlated with serum LH and free T levels and negatively correlated with total body fat and percent body fat, adjusting for AFN. CONCLUSION(S): In normal-weight women with PCOS, serum E2 hyperresponsiveness to rhFSH represents increased AFN, while elevated serum AMH levels reflect opposing effects of stimulatory reproductive (hyperandrogenism and increased AFN) versus inhibitory metabolic (body fat) factors. Given the small number of subjects reported, additional follow-up studies are required to confirm these data.
Copyright © 2017 American Society for Reproductive Medicine. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Antimüllerian hormone; PCOS; adiposity; estradiol; hyperandrogenism

Mesh:

Substances:

Year:  2018        PMID: 29428312      PMCID: PMC5812340          DOI: 10.1016/j.fertnstert.2017.11.017

Source DB:  PubMed          Journal:  Fertil Steril        ISSN: 0015-0282            Impact factor:   7.329


  50 in total

1.  Serum anti-Mullerian hormone as a surrogate for antral follicle count for definition of the polycystic ovary syndrome.

Authors:  P Pigny; S Jonard; Y Robert; D Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2005-12-20       Impact factor: 5.958

Review 2.  Regulation of ovarian follicular development in primates: facts and hypotheses.

Authors:  A Gougeon
Journal:  Endocr Rev       Date:  1996-04       Impact factor: 19.871

3.  Obesity adversely affects serum anti-müllerian hormone (AMH) levels in Caucasian women.

Authors:  Vicky Moy; Sangita Jindal; Harry Lieman; Erkan Buyuk
Journal:  J Assist Reprod Genet       Date:  2015-07-21       Impact factor: 3.412

4.  Pathogenic Anti-Müllerian Hormone Variants in Polycystic Ovary Syndrome.

Authors:  Lidija K Gorsic; Gulum Kosova; Brian Werstein; Ryan Sisk; Richard S Legro; M Geoffrey Hayes; Jose M Teixeira; Andrea Dunaif; Margrit Urbanek
Journal:  J Clin Endocrinol Metab       Date:  2017-08-01       Impact factor: 5.958

5.  Per-follicle measurements indicate that anti-müllerian hormone secretion is modulated by the extent of follicular development and luteinization and may reflect qualitatively the ovarian follicular status.

Authors:  Renato Fanchin; Nabil Louafi; Daniel H Méndez Lozano; Nelly Frydman; René Frydman; Joëlle Taieb
Journal:  Fertil Steril       Date:  2005-07       Impact factor: 7.329

6.  QDR 4500A dual-energy X-ray absorptiometer underestimates fat mass in comparison with criterion methods in adults.

Authors:  Dale A Schoeller; Frances A Tylavsky; David J Baer; William C Chumlea; Carrie P Earthman; Thomas Fuerst; Tamara B Harris; Steven B Heymsfield; Mary Horlick; Timothy G Lohman; Henry C Lukaski; John Shepherd; Roger M Siervogel; Lori G Borrud
Journal:  Am J Clin Nutr       Date:  2005-05       Impact factor: 7.045

7.  Is there any correlation between amh and obesity in premenopausal women?

Authors:  Sezai Sahmay; Taner Usta; Cemal Tamer Erel; Metehan Imamoğlu; Mustafa Küçük; Nil Atakul; Hakan Seyisoğlu
Journal:  Arch Gynecol Obstet       Date:  2012-05-04       Impact factor: 2.344

8.  Anti-Mullerian hormone levels reflect severity of PCOS but are negatively influenced by obesity: relationship with increased luteinizing hormone levels.

Authors:  Athanasia Piouka; Dimitrios Farmakiotis; Ilias Katsikis; Djuro Macut; Spiros Gerou; Dimitrios Panidis
Journal:  Am J Physiol Endocrinol Metab       Date:  2008-10-28       Impact factor: 4.310

9.  Referral bias in defining the phenotype and prevalence of obesity in polycystic ovary syndrome.

Authors:  Uche Ezeh; Bulent O Yildiz; Ricardo Azziz
Journal:  J Clin Endocrinol Metab       Date:  2013-03-28       Impact factor: 5.958

10.  Elevated serum level of anti-mullerian hormone in patients with polycystic ovary syndrome: relationship to the ovarian follicle excess and to the follicular arrest.

Authors:  Pascal Pigny; Emilie Merlen; Yann Robert; Christine Cortet-Rudelli; Christine Decanter; Sophie Jonard; Didier Dewailly
Journal:  J Clin Endocrinol Metab       Date:  2003-12       Impact factor: 5.958

View more
  6 in total

Review 1.  Animal Models to Understand the Etiology and Pathophysiology of Polycystic Ovary Syndrome.

Authors:  Elisabet Stener-Victorin; Vasantha Padmanabhan; Kirsty A Walters; Rebecca E Campbell; Anna Benrick; Paolo Giacobini; Daniel A Dumesic; David H Abbott
Journal:  Endocr Rev       Date:  2020-07-01       Impact factor: 19.871

2.  Ovarian response to follicle-stimulating hormone in women with polycystic ovary syndrome is diminished compared to ovulatory controls.

Authors:  Tracy N H Harrison; R Jeffrey Chang
Journal:  Clin Endocrinol (Oxf)       Date:  2022-03-14       Impact factor: 3.523

Review 3.  Mechanisms of intergenerational transmission of polycystic ovary syndrome.

Authors:  Daniel A Dumesic; Luis R Hoyos; Gregorio D Chazenbalk; Rajanigandha Naik; Vasantha Padmanabhan; David H Abbott
Journal:  Reproduction       Date:  2020-01       Impact factor: 3.906

4.  The Goto-Kakizaki rat is a spontaneous prototypical rodent model of polycystic ovary syndrome.

Authors:  Camille Bourgneuf; Danielle Bailbé; Antonin Lamazière; Charlotte Dupont; Marthe Moldes; Dominique Farabos; Natacha Roblot; Camille Gauthier; Emmanuelle Mathieu d'Argent; Joelle Cohen-Tannoudji; Danielle Monniaux; Bruno Fève; Jamileh Movassat; Nathalie di Clemente; Chrystèle Racine
Journal:  Nat Commun       Date:  2021-02-16       Impact factor: 14.919

5.  Anti-Müllerian Hormone Predictive Levels to Determine The Likelihood of Ovarian Hyper-Response in Infertile Women with Polycystic Ovarian Morphology.

Authors:  Azadeh Akbari Sene; Mahnaz Ashrafi; Nasim Alaghmand-Fard; Neda Mohammadi; Mona Mortezapour Alisaraie; Ahad Alizadeh
Journal:  Int J Fertil Steril       Date:  2021-03-11

6.  Altered m6 A modification is involved in up-regulated expression of FOXO3 in luteinized granulosa cells of non-obese polycystic ovary syndrome patients.

Authors:  Shen Zhang; Wenli Deng; Qiongyou Liu; Peiyu Wang; Wei Yang; Wuhua Ni
Journal:  J Cell Mol Med       Date:  2020-09-01       Impact factor: 5.310

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.